{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:17:50Z","timestamp":1787696270001,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Lipid abnormalities are prevalent among people living with human immunodeficiency virus (HIV) (PLWH) and contribute to increasing risk of cardiovascular events. This study aims to investigate the incidence of dyslipidemia and its risk factors in PLWH after receiving different first-line free antiretroviral regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PLWH who sought care at the Third People's Hospital of Shenzhen from January 2014 to December 2018 were included, and the baseline characteristics and clinical data during the follow-up were collected, including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). The risk factors of dyslipidemia after antiretroviral therapy were analyzed with the generalized estimating equation model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 7623 PLWH included, the mean levels of TC, HDL-C and LDL-C were 4.23\u200a\u00b1\u200a0.85\u200ammol\/L, 1.27\u200a\u00b1\u200a0.29\u200ammol\/L and 2.54\u200a\u00b1\u200a0.65\u200ammol\/L, respectively, and the median TG was 1.17 (IQR: 0.85\u22121.68)\u200ammol\/L. Compared with that in PLWH receiving tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + ritonavir-boosted lopinavir (LPV\/r), zidovudine (AZT) + 3TC + efavirenz (EFV), and AZT + 3TC + LPV\/r, the incidence of dyslipidemia was lower in PLWH receiving TDF + 3TC + EFV. In multivariate analysis, we found that the risks of elevations of TG, TC, and LDL-C were higher with TDF + 3TC + LPV\/r (TG: odds ratio [OR] = 2.82, 95% confidence interval [CI]: 2.55\u22123.11, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001; TC: OR\u200a=\u200a1.24, 95% CI: 1.14\u22121.35, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001; LDL: OR\u200a=\u200a1.06, 95% CI: 1.00\u22121.12, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.041), AZT + 3TC + EFV (TG: OR\u200a=\u200a1.41, 95% CI: 1.28\u22121.55, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001; TC: OR\u200a=\u200a1.43, 95% CI: 1.31\u22121.56, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001; LDL: OR\u200a=\u200a1.18, 95% CI: 1.12\u22121.25, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001), and AZT + 3TC + LPV\/r (TG: OR\u200a=\u200a3.08, 95% CI: 2.65\u22123.59, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001; TC: OR\u200a=\u200a2.40, 95% CI: 1.96\u22122.94, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001; LDL: OR\u200a=\u200a1.52, 95% CI: 1.37\u22121.69, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001) than with TDF + 3TC + EFV, while treatment with TDF + 3TC + LPV\/r was less likely to restore HDL-C levels compared with TDF + 3TC + EFV (OR\u200a=\u200a0.95, 95% CI: 0.92\u22120.97, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001). In addition to antiretroviral regimens, antiretroviral therapy duration, older age, overweight, obesity and other traditional factors were also important risk factors for dyslipidemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The incidence of dyslipidemia varies with different antiretroviral regimens, with TDF + 3TC + EFV having lower risk for dyslipidemia than the other first-line free antiretroviral regimens in China.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001245","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T20:01:38Z","timestamp":1605124898000},"page":"2808-2815","source":"Crossref","is-referenced-by-count":24,"title":["Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen"],"prefix":"10.1097","volume":"133","author":[{"given":"Li-Qin","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ye","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Mei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Kun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ning","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Zhi","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Mei","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"R1-20231219","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cjca.2018.11.005","article-title":"Lipid abnormalities in persons living with HIV infection","volume":"35","author":"Waters","year":"2019","journal-title":"Can J Cardiol"},{"key":"R2-20231219","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trsl.2016.12.007","article-title":"HIV and its relationship to insulin resistance and lipid abnormalities","volume":"183","author":"Non","year":"2017","journal-title":"Transl Res"},{"key":"R3-20231219","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","article-title":"Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different drugs associated with different lipid profiles?","volume":"189","author":"Fontas","year":"2004","journal-title":"J Infect Dis"},{"key":"R4-20231219","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"R5-20231219","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/CIRCULATIONAHA.118.036211","article-title":"Time to recognize HIV infection as a major cardiovascular risk factor","volume":"138","author":"Hsue","year":"2018","journal-title":"Circulation"},{"key":"R6-20231219","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-M\u00f8ller","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-20231219","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-20231219","first-page":"629","article-title":"Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the Diagnosis and Treatment of HIV\/AIDS (2011 Edition)","volume":"29","author":"Group","year":"2011","journal-title":"Chin J Infect Dis"},{"key":"R9-20231219","first-page":"867","article-title":"Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2018) (in Chinese)","volume":"57","year":"2018","journal-title":"Chin J Intern Med"},{"key":"R10-20231219","first-page":"122","article-title":"Prevalence and influencing factors of dyslipidemia among treatment-naive HIV-infected individuals in Shenzhen in 2018","volume":"33","author":"Sun","year":"2020","journal-title":"Infect Dis Info"},{"key":"R11-20231219","first-page":"5","article-title":"Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population","volume":"23","year":"2002","journal-title":"Chin J Epidemiol"},{"key":"R12-20231219","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R13-20231219","first-page":"42","article-title":"Key points and interpretation of Chinese expert consensus on hypertriglyceridemia and its cardiovascular risk management","volume":"32","author":"Ye","year":"2017","journal-title":"Chin Circul J"},{"key":"R14-20231219","first-page":"1651","article-title":"Cardiovascular abnormalities in HIV-infected individuals","author":"Hsue","year":"2019","journal-title":"Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set"},{"key":"R15-20231219","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1017\/gheg.2018.7","article-title":"HIV treatment is associated with a two-fold higher probability of raised triglycerides: Pooled Analyses in 21 023 individuals in sub-Saharan Africa","volume":"3","author":"Ekoru","year":"2018","journal-title":"Glob Health Epidemiol Genom"},{"key":"R16-20231219","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"key":"R17-20231219","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"R18-20231219","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R19-20231219","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","article-title":"Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study","volume":"100","author":"P\u00e9riard","year":"1999","journal-title":"Circulation"},{"key":"R20-20231219","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/jmv.23543","article-title":"Improved metabolic profile after switch to darunavir\/ritonavir in HIV positive patients previously on protease inhibitor therapy","volume":"85","author":"Ucciferri","year":"2013","journal-title":"J Med Virol"},{"key":"R21-20231219","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/nm1201-1327","article-title":"HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia","volume":"7","author":"Liang","year":"2001","journal-title":"Nat Med"},{"key":"R22-20231219","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0163-7827(02)00046-2","article-title":"Effects of HIV protease inhibitor therapy on lipid metabolism","volume":"42","author":"Hui","year":"2003","journal-title":"Prog Lipid Res"},{"key":"R23-20231219","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/00002030-200112070-00007","article-title":"An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride\/low HDL levels in treated HIV patients","volume":"15","author":"Fauvel","year":"2001","journal-title":"AIDS"},{"key":"R24-20231219","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1373\/clinchem.2006.069583","article-title":"Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation","volume":"52","author":"Guardiola","year":"2006","journal-title":"Clin Chem"},{"key":"R25-20231219","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/QAD.0b013e32823644ff","article-title":"Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era","volume":"21","author":"Joy","year":"2007","journal-title":"AIDS"},{"key":"R26-20231219","doi-asserted-by":"crossref","first-page":"53E","DOI":"10.1016\/j.amjcard.2005.06.006","article-title":"Recent national cholesterol education program adult treatment panel III update: adjustments and options","volume":"96","author":"Stone","year":"2005","journal-title":"Am J Cardiol"},{"key":"R27-20231219","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0b013e328341f925","article-title":"Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care","volume":"25","author":"Crane","year":"2011","journal-title":"AIDS"},{"key":"R28-20231219","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3851\/IMP3051","article-title":"Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study","volume":"21","author":"Kamara","year":"2016","journal-title":"Antivir Ther"},{"key":"R29-20231219","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1179\/1945577115Y.0000000004","article-title":"Comparative effectiveness of tenofovir in treatment-na\u00efve HIV-infected patients: systematic review and meta-analysis","volume":"16","author":"Hemkens","year":"2015","journal-title":"HIV Clin Trials"},{"key":"R30-20231219","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jac\/dkp462","article-title":"Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients","volume":"65","author":"Valantin","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R31-20231219","doi-asserted-by":"crossref","first-page":"e0116297","DOI":"10.1371\/journal.pone.0116297","article-title":"A randomized comparative trial of continued abacavir\/lamivudine plus efavirenz or replacement with efavirenz\/emtricitabine\/tenofovir DF in hypercholesterolemic HIV-1 infected individuals","volume":"10","author":"Moyle","year":"2015","journal-title":"PLoS One"},{"key":"R32-20231219","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2007.10.018","article-title":"HIV infection and high density lipoprotein metabolism","volume":"199","author":"Rose","year":"2008","journal-title":"Atherosclerosis"},{"key":"R33-20231219","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/QAI.0b013e318219a3d1","article-title":"Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, Tanzania","volume":"57","author":"Armstrong","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R34-20231219","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.biopha.2012.01.005","article-title":"The feature of metabolic syndrome in HIV naive patients is not the same of those treated: results from a prospective study","volume":"66","author":"Bonfanti","year":"2012","journal-title":"Biomed Pharmacother"},{"key":"R35-20231219","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00002030-200403260-00017","article-title":"Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients","volume":"18","author":"Negredo","year":"2004","journal-title":"AIDS"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:09:50Z","timestamp":1703002190000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":35,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001245","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]}}}